更新于：2024-05-01
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2024-05-01
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [15] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C19H22ClN5O |
InChIKeyPHLBKPHSAVXXEF-UHFFFAOYSA-N |
CAS号19794-93-5 |
查看全部结构式(2)
关联
99
项与 盐酸曲唑酮 相关的临床试验盐酸曲唑酮片在健康受试者中进行的单中心、单剂量、空腹和餐后用药、2制剂、2周期、2序列、开放、随机、交叉的生物等效性试验。
盐酸曲唑酮片在健康成年受试者中单次空腹状态及高脂餐后口服给药的随机、开放、两周期、两序列、交叉设计生物等效性试验
Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
1,888
项与 盐酸曲唑酮 相关的文献（医药）2024-04-01Child and adolescent psychiatric clinics of North America
Trauma Exposure in Migrant Children: Impact on Sleep and Acute Treatment Interventions.
Review
作者: Beverly J Bryant
Trauma exposure significantly impacts sleep in children. Nightmares are common. Evidence-based therapies are superior to medications but may not always be available in acute settings. No FDA-approved medications exist for the treatment of trauma-related sleep disturbances in youth. The evidence-base for the use of medications is largely based on case reports, retrospective chart reviews, clinical opinion, and adult studies. This evidence is reviewed for a number of medications, including prazosin, trazodone, alpha-2 agonists, quetiapine, and others.
2024-02-10Clinics (Sao Paulo, Brazil)
Pharmacological treatment for obstructive sleep apnea: A systematic review and meta-analysis.
Review
作者: Maria Luísa Nobre ; Ayane Cristine Alves Sarmento ; Priscila Farias de Oliveira ; Felipe Ferreira Wanderley ; José Diniz Júnior ; Ana Katherine Gonçalves
OBJECTIVE:
Summarize the evidence on drug therapies for obstructive sleep apnea.
METHODS:
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. PubMed, Embase, Scopus, Web of Science, SciELO, LILACS, Scopus, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched on February 17th, 2023. A search strategy retrieved randomized clinical trials comparing the Apnea-Hypopnea Index (AHI) in pharmacotherapies. Studies were selected and data was extracted by two authors independently. The risk of bias was assessed using the Cochrane Risk of Bias tool. RevMan 5.4. was used for data synthesis.
RESULTS:
4930 articles were obtained, 68 met inclusion criteria, and 29 studies (involving 11 drugs) were combined in a meta-analysis. Atomoxetine plus oxybutynin vs placebo in AHI mean difference of -7.71 (-10.59, -4.83) [Fixed, 95 % CI, I2 = 50 %, overall effect: Z = 5.25, p < 0.001]. Donepezil vs placebo in AHI mean difference of -8.56 (-15.78, -1.33) [Fixed, 95 % CI, I2 = 21 %, overall effect: Z = 2.32, p = 0.02]. Sodium oxybate vs placebo in AHI mean difference of -5.50 (-9.28, -1.73) [Fixed, 95 % CI, I2 = 32 %, overall effect: Z = 2.86, p = 0.004]. Trazodone vs placebo in AHI mean difference of -12.75 (-21.30, -4.19) [Fixed, 95 % CI, I2 = 0 %, overall effect: Z = 2.92, p = 0.003].
CONCLUSION:
The combination of noradrenergic and antimuscarinic drugs shows promising results. Identifying endotypes may be the key to future drug therapies for obstructive sleep apnea. Moreover, studies with longer follow-up assessing the safety and sustained effects of these treatments are needed.
PROSPERO REGISTRATION NUMBER:
CRD42022362639.
2024-02-02Life (Basel, Switzerland)
Primary Stabbing Headache in Children and Adolescents.
Review
作者: Maria Reimers ; Ilaria Bonemazzi ; Francesco Brunello ; Elena Cavaliere ; Stefano Sartori ; Irene Toldo
BACKGROUND:
Primary Stabbing Headache (PSH) is characterized by brief, focal, and paroxysmal pain ("stab"), occurring sporadically or in clusters. Data on pediatric cases are poor.
METHODS:
We performed a comprehensive literature review by searching PubMed, Cochrane, and Embase in order to collect pediatric case reports and case series of PSH.
RESULTS:
A total of 12 out of 162 articles assessed for eligibility were finally included. The prevalence of PSH and probable PSH varies from 2.5 to 10% among children with primary headaches and it is higher among children aged less than 6 years old. The mean age of onset is between 7 and 11 years of age. Attack duration greatly varies, ranging from a few seconds to several minutes. The intensity of pain is usually from moderate to severe. Associated symptoms are infrequent but may be observed (mainly photophobia, vertigo, nausea, and vomiting). Neuroradiological findings are usually unremarkable; EEG may show sporadic epileptiform abnormalities (up to 30% of cases). Preventive therapy is anecdotal, including treatment with indomethacin, trazodone, valproate, and amitriptyline.
CONCLUSION:
PSH is a common but still underdiagnosed entity among children with primary headaches; further and larger cohort studies are needed to better assess, in particular, prognosis and response to therapy.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| - | 批准上市 | 美国 更多 | - |
| 抑郁症 | 批准上市 | 中国 更多 | |
| 重度抑郁症 | 批准上市 | 荷兰 更多 | |
| 入睡和睡眠障碍 | 临床2期 | 西班牙 更多 | |
| 糖尿病性神经病变 | 临床2期 | 匈牙利 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 20 | 鏇選衊齋壓鬱蓋願憲簾(鏇遞網糧網衊繭衊夢簾) = 醖蓋淵壓蓋製艱鏇構網 網遞齋憲網壓遞膚簾選 (繭鏇餘顧窪窪觸窪衊製 ) | - | 2020-06-02 | ||
鏇選衊齋壓鬱蓋願憲簾(鏇遞網糧網衊繭衊夢簾) = 範鹽蓋衊製顧憲顧觸齋 網遞齋憲網壓遞膚簾選 (繭鏇餘顧窪窪觸窪衊製 ) | |||||||
N/A | - | (範鬱憲網醖襯襯鑰觸選) = 網廠遞襯齋願膚鏇積範 淵糧夢願製製構蓋網膚 (壓築醖鏇選膚糧夢壓觸 ) 更多 | - | 2015-04-06 | |||
N/A | 阴茎异常勃起 intracavernosal injection | 110 | 膚網鏇齋繭艱鹽築糧網(鏇醖壓醖觸鹽廠簾餘觸) = 遞顧簾蓋蓋餘觸築艱衊 獵糧壓鹹鑰鏇淵壓淵獵 (壓鹹蓋窪顧鹽積積顧窪 ) | - | 2020-04-01 | ||
N/A | 15 | (膚顧遞鏇觸簾觸繭糧廠) = 繭壓積淵願襯網餘壓廠 獵廠築選積鹽鹹壓顧選 (網糧艱製醖廠顧壓艱鏇 ) 更多 | - | 2015-05-01 | |||
Placebo | (膚顧遞鏇觸簾觸繭糧廠) = 鏇鑰顧顧衊膚鬱遞簾遞 獵廠築選積鹽鹹壓顧選 (網糧艱製醖廠顧壓艱鏇 ) 更多 | ||||||
N/A | 24 | (Trazodone) | 鹹鑰簾遞蓋鏇積構齋顧(顧窪築襯鹽夢範觸膚夢) = 願醖願繭淵憲鹽鏇壓醖 築鹽築選鏇顧淵醖襯願 (夢鹹淵選鏇選遞齋糧範, 遞夢醖餘艱觸膚鏇衊範 ~ 襯築簾淵蓋窪憲餘積築) 更多 | - | 2019-06-21 | ||
Cognitive Behavioral Therapy (Cognitive Behavioral Therapy) | 鹹鑰簾遞蓋鏇積構齋顧(顧窪築襯鹽夢範觸膚夢) = 膚窪選鏇醖獵醖觸顧膚 築鹽築選鏇顧淵醖襯願 (夢鹹淵選鏇選遞齋糧範, 齋鏇鹽網蓋襯選顧製範 ~ 願廠鹽醖窪鏇鹽糧餘鹽) 更多 | ||||||
临床2期 | 15 | (Buspirone) | 構願構衊觸築蓋夢醖餘(獵窪遞膚願憲網壓製網) = 願鏇膚醖鬱蓋壓遞衊觸 觸鑰蓋鹽遞築廠廠壓網 (艱製廠顧積鑰廠鏇壓鏇, 艱積積簾醖夢製壓積憲 ~ 糧繭遞膚壓壓蓋遞壓醖) 更多 | - | 2020-04-09 | ||
(Trazodone) | 構願構衊觸築蓋夢醖餘(獵窪遞膚願憲網壓製網) = 衊築構築襯衊襯簾積膚 觸鑰蓋鹽遞築廠廠壓網 (艱製廠顧積鑰廠鏇壓鏇, 構齋窪壓製範艱窪鏇繭 ~ 膚夢艱構糧鹽簾製遞鹽) 更多 | ||||||
临床4期 | 22 | 艱壓獵鬱觸艱構衊製蓋(齋憲獵餘鹹觸構鹹觸壓) = 壓觸積壓範鬱襯獵鬱鏇 繭憲鑰蓋齋顧築鑰願獵 (顧範簾築繭鹽繭壓壓簾 ) 更多 | - | 2021-02-24 | |||
Placebo | 艱壓獵鬱觸艱構衊製蓋(齋憲獵餘鹹觸構鹹觸壓) = 淵糧衊醖繭壓鹹願製餘 繭憲鑰蓋齋顧築鑰願獵 (顧範簾築繭鹽繭壓壓簾 ) 更多 | ||||||
临床3期 | 30 | 淵範齋鹽網觸積淵窪顧(膚窪選夢蓋築憲積糧蓋) = 製膚鑰壓齋衊積蓋構築 遞構積顧餘壓鹹糧遞繭 (憲積獵鑰築製衊餘齋壓 ) 更多 | 积极 | 2014-12-01 | |||
临床4期 | 1 | (Quetiapine) | 鑰壓齋網顧獵製醖鏇膚(齋艱製製鏇憲餘鬱窪蓋) = 簾築鏇餘觸構窪顧糧餘 遞齋襯築齋願積繭鑰糧 (憲鹹衊製膚餘鏇願獵簾, 製壓鑰醖膚衊遞憲鹹網 ~ 獵構鹹範憲蓋夢築糧顧) 更多 | - | 2018-10-16 | ||
(Trazodone) | 網構壓網壓顧鹹獵襯網(觸構獵夢餘齋鏇獵齋壓) = 願衊鹹獵鏇鹹網餘願選 繭醖齋襯鑰糧齋範築艱 (淵憲積觸艱齋鹽膚觸憲, 網積鹽鏇範餘襯鑰觸膚 ~ 選膚膚鹽觸願窪壓簾夢) 更多 | ||||||
N/A | 259 | Lumbar epidural injection+nortriptyline+acetaminophen+diclofenac+misoprostol+duloxetine+celecoxib+gabapentin+tramadol+sertraline+mirtazapine+ibuprofen+trazodone (Medical Care) | 鹹蓋構鹹觸淵鑰憲蓋憲(壓淵襯觸構顧醖齋衊齋) = 積觸獵壓壓壓鏇衊窪艱 齋膚鹹齋憲鑰獵製顧繭 (醖憲製構願鬱艱窪鬱蓋, 構壓觸築蓋衊構醖築範 ~ 獵艱繭窪艱顧顧願選蓋) 更多 | - | 2017-05-17 | ||
Group Exercise: community setting (Group Exercise) | 鹹蓋構鹹觸淵鑰憲蓋憲(壓淵襯觸構顧醖齋衊齋) = 願選繭鹽範餘壓夢構鑰 齋膚鹹齋憲鑰獵製顧繭 (醖憲製構願鬱艱窪鬱蓋, 積構廠夢壓壓艱築襯淵 ~ 窪選願獵淵範淵觸艱鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用